CARsgen’s CT0596 and CT1190B Abstracts Published on EHA Website

SHANGHAI, China, May 12, 2026, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the abstracts of CT0596 (an allogeneic CAR T-cell product targeting BCMA), and CT1190B (an allogeneic CAR T-cell product targeting CD19/CD20) are available on the European Hematology Association (“EHA”) website. Please refer to the link below for details. Title FIRST-IN-HUMAN STUDY OF CT0596, AN ALLOGENEIC BCMA CAR T IN RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIMARY PLASMA CELL LEUKEMIA: SAFETY, EFFICACY, AND PHARMACOKINETIC AT RECOMMENDED DOSE Abstract Number PF784 Poster Presentation Time Poster Session 1 on Friday, June 12 (18:45 - 19:45 CEST) Abstract Link https://library.ehaweb.org/eha/2026/eha-2026/4207772/juan.du.first-in-human.study.of.ct0596.an.allogeneic.bcma.car.t.in.relapsed.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DPF784 Title FIRST IN HUMAN STUDY OF CT1190B, AN ALLOGENEIC ANTI-CD19/CD20 CAR T-CELL THERAPY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA Abstract Number PS2064 Poster Presentation Time Poster Session 2 on Saturday, June 13 (18:45 - 19:45 CEST) Abstract Link https://library.ehaweb.org/eha/2026/eha-2026/4208615/shiguang.ye.first.in.human.study.of.ct1190b.an.allogeneic.anti-cd19.cd20.car.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3DPS2064 About CT0596 CT0596 is an allogeneic BCMA-targeted CAR-T therapy developed using CARsgen’s proprietary THANK-u Plus® platform. It is currently being evaluated in IITs for R/R MM or PCL. CT0596 demonstrated preliminary favorable tolerability and encouraging efficacy signals. Further investigation is planned in additional plasma cell malignancies and autoimmune diseases mediated by autoreactive plasma cells. The Company plans to initiate Phase Ib clinical trials for R/R MM and primary PCL in 2026. About CT1190B CT1190B is a CD19/CD20-targeted allogeneic CAR-T cell therapy developed based on CARsgen’s THANK-u Plus® platform. Ongoing clinical trials include IITs for R/R B-NHL, and for moderate-to-severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc). The Company plans to initiate Phase Ib clinical trials for R/R B-NHL in 2026. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit https://www.carsgen.com/ Public Relations: [email protected] Investor Relations: [email protected] Previous Next

The release as fetched from its publisher. carsgen.com ↗